Abbisko Therapeautics
Ejecutivos
Ver el organigrama con sus 6 ejecutivos principales
Biografías más buscadas en Abbisko Therapeautics
- Jia Feng, Head of Human Resource
- Jing Ji, Chief Medical Officer
- Zidong Zhang, Chief Financial Officer
Crear su alerta
para seguir los movimientos de los ejecutivos en Abbisko Therapeautics.
Biotecnología
Abbisko Therapeautics tiene 2.284 competidores entre los que se incluyen Lonza (Suiza), Eurofins (Luxemburgo) y Adaptive Phage Therapeutics (Estados Unidos).
Popular M&A news in Biotecnología
- Karius acaba de anunciar una recaudación de fondos de 100 millones de dólares. (publicado el 3 de mayo de 2024).
- Transcarent acaba de anunciar una recaudación de fondos de 126 millones de dólares. (publicado el 2 de mayo de 2024).
- WindRose Health Investors has announced the acquisition of SubjectWell (publicado el 2 de mayo de 2024).
Otros contactos sugeridos en el sector Biotecnología
Noticias
Últimos comunicados de prensa de Abbisko Therapeautics
- Abbisko Therapeutics - 上海和誉生物医药科技有限公司-Abbisko Therapeutics Announces Irpagratinib, an Innovative FGFR4 inhibitor,has been Granted ODD by the U.S. FDA for the Treatment of HCC
- Abbisko Therapeutics - 上海和誉生物医药科技有限公司-2024 AACR | Abbisko Therapeutics Presented 3 Pre-clinical Research Results with Oral and Poster Presentations
- Abbisko Therapeutics - 上海和誉生物医药科技有限公司-Abbisko Therapeutics Completed All Patient Enrollment for The Global Phase III TGCT Trial of Its CSF-1R Inhibitor – Pimicotinib（ABSK021）
- Abbisko Therapeutics - 上海和誉生物医药科技有限公司-Abbisko Therapeutics completed the First Patient Dose of Next-generation EGFR Exon20ins Inhibitor ABSK112
- Abbisko Therapeutics - 上海和誉生物医药科技有限公司-2024 ESMO TAT Oral Presentation — Abbisko Therapeutics presented preliminary first-in-human trial results of its selective FGFR2/3 inhibitor ABSK061
- Abbisko Therapeutics - 上海和誉生物医药科技有限公司-2024 AACR | Abbisko Therapeutics will present 3 pre-clinical research results with oral presentation and posters
- Abbisko Therapeutics - 上海和誉生物医药科技有限公司-US$70 million Arrived! Abbisko Therapeutics Announced it Received Upfront Payment Pursuant to the Licensing Agreement for Pimicotinib (ABSK021) with Merck
- Abbisko Therapeutics - 上海和誉生物医药科技有限公司-Merck Delegation Visited Abbisko Shanghai R&D Center
- Abbisko Therapeutics - 上海和誉生物医药科技有限公司-Abbisko Therapeutic announces that EMA has granted orphan drug designation for its CSF-1R inhibitor Pimicotinib （ABSK021）
- Abbisko Therapeutics - 上海和誉生物医药科技有限公司-Abbisko Therapeutic Completed the First Patient Dose in Phase I Clinical Trial for Novel Small Molecule CD73 Inhibitor ABSK051
- View more press releases Close
Redes sociales sobre Abbisko Therapeautics
- Abbisko Therapeautics en Wikipedia, Google News y Yahoo Finance
- Abbisko Therapeautics en LinkedIn, Twitter y YouTube
Ponerse en contacto
Contactar a través de e-mail con sus ejecutivos Zidong Zhang 
Llame a Abbisko Therapeautics al +86 ...
